Skip to main content

Compugen, Mayo Clinic to Hunt, Validate Biomarkers for Atherosclerotic Plaque

NEW YORK (GenomeWeb News) — Compugen and the Mayo Clinic plan to discover and validate biomarkers that could detect plaques linked to heart and brain diseases, the company said today.
 
Under the agreement, Compugen will retain exclusive commercialization rights to any products that result from the collaboration, which aims to find biomarkers for atherosclerotic plaques in coronary artery disease and in cerebrovascular disease.
 
Mayo Clinic will provide the biological materials for the research in exchange for undisclosed financial compensation.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.